Funding for this research was provided by:
National Institutes of Health (5T32CA009695-27)
Arbor Pharmaceuticals
Accuray
Bristol-Myers Squibb Foundation
Novartis Pharmaceuticals Corporation
Article History
Accepted: 24 November 2021
First Online: 2 February 2022
Declarations
:
: Michael Zhang (Funding by the National Institutes of Health (5T32CA009695-27). Michael Lim (Funding from Arbor Pharmaceuticals, Accuray, BMS, Novartis, Biohaven; consultant: BMS, Merck, SQZ Biotechnologies, Tocagen, VBI, Biohaven; patents: combining focused radiation and immunotherapy, combining local chemotherapy and immunotherapy).
: This article does not contain any studies with human or animal subjects performed by any of the authors.